The endometrium shows a marked cestrogenic effect to begin with and this is reduced when the progestogen is added. Thus, in the first week of therapy, the glands are large and plentiful and vary from straight to moderately tortuous. The lining epithelium is tall columnar with oval nuclei arranged in a markedly disordered fashion. There are frequent mitoses. The stromal cells are widely separated by the oedema. Capillaries and sinusoids in most sections are prominent. Over the next six days there is pseudo-stratification of the epithelium and subnuclear vacuoles become apparent although the progestogen has not yet been added. In the last-five days with the combined treatment, intra-epithelial vacuoles are conspicuous in most glands and there is some secretion in the lumen but the endometrium is by no means normal for this stage.
We are also studying other varieties of sequential therapy, e.g. an 11/10-day regime with different doses of both cestrogens and other progestogens.
Clinical Findings
Larger doses of these same progestogen/cestrogen compounds used for gynxcological purposes have been shown to cause enlargement of the uterus and of fibroids, pelvic congestion and swelling of the thyroid, &c. However, at oral contraceptive doses as used in this country, there have been no signs of any of these phenomena. Indeed, while some patients experience early side-effects, many more are delighted to find that they are relieved of many side-effects of the so-called 'normal' menstrual cyclee.g. premenstrual tension, dysmenorrhcea, migraine, breast discomfort. It is my experience that treatment of gynaecologica,l conditions such as functional uterine bleeding, dysmenorrhmea, premenstrual tension, irregular menstruation and even endometriosis, which call for progestogen therapy, is effected equally well with,-the oral contraceptive regime at a smaller dosage and with fewer side-effects. Development of oral contraception has been rapid and there has been great co-operation from the pharmaceutical industry. Failures have been few and complications have seldom proved serious. However, there is a growing realization that these cestrogenic and progestational drugs have constitutional effects upon various systems of the body and that trouble may only become evident after prolonged treatment. An account of the difficulties and dangers inherent in the use of these drugs divides naturally into those immediate complications that have in fact been encountered and the more remote contingencies that at present remain speculative.
The rate of unplanned pregnancies has been commendably low and approximates to one pregnancy per 100 woman-years. Pincus (1961) gives the figure as 1 *2 % for 7,000 cycles on Conovid, while gives an almost identical figure of 11 pregnancies in 14,412 cycles among women taking part in the trials of 7 different compounds. This figure, though incomparably better than those of 14 and 12 quoted by Venning (1961) for the male condom and female diaphragm, is still sufficiently substantial to make it worthy of analysis. Accordingly those failures that have come-to our notice in Birmingham since trials of oral contraceptives began in 1960 are discussed below. 13 Failure due to inadequate medical instruction has not been encountered in clinic patients but one unplanned pregnancy occurred in a woman who alleged that her practitioner had advised her to take the pill only when she had intercourse and another when a patient had been told to take it on alternate days. Our main experience of failure in the Family Planning Association Clinic was during our first ill-fated trial (Eckstein et al. 1961) when patients were given norethynodrel 2-3 mg with mestranol 0-036 mg: this resulted in 14 pregnancies among 48 patients within three months, yet subsequent experience has repeatedly confirmed that norethynodrel 2 5 mg with mestranol 0-1 mg (Conovid-E) is uniformly successful, thus emphasizing the critical dosage of oestrogen with low levels of progestogen. Subsequent experience has been happier. Out of just over 400 patients subjected to careful scrutiny and documentation for periods up to three and a half years and averaging over one and a half years there have been 8 recorded pregnancies, while 500 others have been supplied with oral contraceptives more recently without coming under such close observation and no pregnancy has been recorded among them. Of these 8 pregnancies, 4 have been conceived by women regarded as entirely unreliable by the doctor most closely concerned, who considers their statements and record card to be quite inaccurate, with repeated discrepancies between the number of tablets remaining and those recorded on the charts. The other 4 are more significant. One woman who had used the method satisfactorily for some months developed gastroenteritis and vomited her tablet on three successive days (the 15th, 16th, 17th days of cycle). She took her next 4 tablets properly, had an episode of bleeding and then resumed medication but, apparently, conceived during her next cycle and had a baby weighing 7j lb thirty-eight weeks later. Another patient conceived probably as a result of going away for a week-end and missing her pills on the 16th and 17th days of cycle, after which there was amenorrheea and a confirmed abortion. These cases show again how critical is the dosage for some women. There have recently been two further pregnancies in women who appear to have taken their tablets correctly: in one there is a slight element of doubt regarding her veracity, while the other (who incidentally had been one of the failures in the 1960 trial) had so much breakthrough bleeding as to make her 'cycle control' quite inadequate, yet the pregnancy does not seem to have been due to any failure to comply with instructions. Finally, one other woman alleged that the pill had failed but it was shown that she had already been pregnant when medica-tion started, the pregnancy being masked by the fact that she had a false period of four days' bleeding a fortnight after conception.
There are some immediate complications of oral contraception that are sufficiently common to be called 'side-effects' and these include nausea, mammary discomfort, headache, weight gain and irregularity of the menstrual cycle. The incidence of these troubles has been carefully observed and may vary among the drugs employed, but there is a strong tendency towards spontaneous improvement. There also seems to be an element of emotion in the causation of these symptoms, Wiseman (1963) having shown that irregularity of uterine bleeding occurs twice as often among women taking the tablet in a free trial as among those purchasing it at the clinic. Personal experience in gynecology confirms that the prescription of identical preparations to control pathological bleeding will be rejected, on account of nausea and vomiting, far more frequently than among women taking them for contraception. Nevertheless a few patients find that nausea makes this form of contraception intolerable and a greater number is considerably upset by the shortening of the cycle that we call 'breakthrough bleeding'. Another side-effect is a noticeable change in libido, and in early trials this seemed to operate equally in a positive and negative direction. Recently an increased number of women have been troubled by lowered libido and it is uncertain how far this may be emotional or hormonal in origin. It has been enough to make two women withdraw from oral contraception and they both reported immediate improvement from this symptom.
There remain two immediate complications that may endanger life. The association between oral contraceptive agents and an increased coagulability of the blood has been widely advertised following reports of serious thrombo-phlebitis and embolic complications (McIntyre et al.
1962
), but although it is admitted that hypercoagulability may exist in some women (Egeberg & Owren 1963) the danger seems no more than that encountered in normal pregnancy. The other danger lies in the effective property of most of these drugs to control pathological uterine bleeding, with the risk that serious uterine disease may be masked and diagnosis delayed. Similarly there remains the possibility that pathological bleeding might be regarded as nothing worse than loss of cycle control and treated by the increased dosage of the contraceptive agent often recommended for the control of breakthrough bleeding. In either event there might be delay in the patient reaching the gynecologist.
Section ofObstetrics and Gynwcology
Remote Hazards The possibility that women who have taken oral contraceptives regularly for a significant length of time might find themselves exposed to the risk of irreversible effects is something that has caused concern to many. Some of these possibilities arise from the observed results of animal experiments and they were set out by Sir Charles Dodds (1962) in the Annual Lecture to the Society of Endocrinology. These hazards may be considered under the headings of malignancy, ovarian dysfunction and other endocrine effects.
Malignancy: Little is known regarding the etiology of cancer of the breast, ovaries and pituitary in the human but experimental work on animals has shown that oral contraceptive drugs might produce tumours in some species in the pituitary (Dodds 1962) and in the ovary (Lancet 1963) . Regarding uterine tumours in the human the facts are better established. Myomata have been shown to undergo rapid development from the stimulus of uninterrupted dosage with these contraceptive hormones in high concentration (Andrews et al. 1959 ) and uterine adenomyosis has been reported in hysterectomy specimens after cyclic dosage (Mills 1962) . Cervical cancer seems to be linked statistically with the habit of sexual intercourse from an early age, so that any reported increase in incidence might be reasonably attributed to the greater frequency of unrestricted intercourse that this form of contraception allows. Corpus cancer usually arises in the relatively infecund woman but there is an increased incidence in women with cestrogenic ovarian tumours and a suspicion exists that the unrestricted use of cestrogen after the menopause might be a factor. It is unlikely that cyclic administration of cestrogen at an earlier age would be operative, especially when combined with a progestational drug that has been used in the therapy of established endometrial cancer (Kelley & Baker 1961) . However, a more recent report (Poel & Haran-Ghera 1963) has shown that, under experimental conditions, progesterone may increase the metastatic spread of some tumours and doubt must still remain.
Ovarian dysfunction: We have little knowledge of the long-term action of these drugs upon the human ovary but both clinical and laboratory work suggests that ovulation is re-established rapidly at the conclusion of each contraceptive course (Loraine et al. 1963) . Our knowledge of the factors that influence the rate of follicle atresia is still limited (Jones & Krohn 1961 ) nor can we altogether explain why the climacteric should occasionally be an immediate sequel to a pregnancy. It is not beyond the realm ofpossibility that women who voluntarily inhibit ovulation for perhaps twenty years of reproductive life might so diminish the rate of follicle atresia as to postpone the climacteric and find unexpected fertility at an advanced age. It will be interesting to find out.
Other endocrine effects: There remain other possible disorders of physiology relating to the action of these contraceptive hormones on other endocrine glands. The cestrogen content is sufficient to alter adrenal cortical function (Layne et al. 1962) . A depression of thyroid function has been reported with larger doses (Brit. med. J. 1963) and it is possible that goitre might be induced in sensitive subjects. A degree of androgenicity has been found in various of the progestogens so that, after a number of years, virilization might become evident. There have been reports that high dosage of these steroids may lead to impairment ofcarbohydrate tolerance in diabetes (Lebherz & Forbes 1961) and the glucose tolerance test may give a false result.
Conclusion
Oral contraceptive agents have a wide appeal and a low rate of failure when taken properly. There are certain difficulties in their administration of which the most obvious is the inconvenient shortening of the menstrual cycle in some women. There are few immediate dangers. The risk of thrombosis and embolism has been largely discounted and possible masking of serious pelvic disease may be more theoretical than real.
The risk of long-term hazards cannot yet be denied. These include a possible increased incidence of tumours, benign and malignant, in the genital tract and elsewhere. There is a possibility of other endocrine and biochemical dysfunctions that may not always be reversible and a chance of significant change in the occurrence of the climacteric.
The individual may well feel disposed to take a calculated risk and balance the certainty of convenient contraception against the chance hazard of future trouble. Medical authorities, however, would do well to insist that long-term research should not be jeopardized by indiscriminate prescribing of these drugs, and that some central registry should keep track of all these patients with records of the type of drug, the number of cycles of treatment and any intervals between the courses.
Only thus may it ultimately be possible to dispel our fears of remote hazards and then (and not until then) will we be able to recommend these drugs to the under-developed countries, knowing that the West will not again be introducing to the East a commodity as lethal as its cigarettes. There do not appear to be any dangers from the short-term use of oral contraceptives of the progestogen-cestrogen type. Until some twenty years of experience has accumulated, it will not be possible really to find out the long-term dangers. A number of these have been predicted, either on the basis of pure speculation by analogy with supposedly comparable experimental animal observations or from recorded data from human use.
It has been suggested that oral contraceptives may cause the development of ovarian cysts or atrophy or, yet again, the preservation of pri-. mordial follicles so that fertility may be retained into the 60s or later. No one has actually seen ovarian cystic change in treated patients, though there is evidence that pre-existing ovarian cysts, may disappear; on the other hand, direct observa-. tions on the ovaries indicate that the appearances are unchanged within the first few cycles of use, resemble those of post-menopausal ovaries after about one year of use but, within a few months of cessation of use, return to normal showing that structure as well as function recovers rapidly. The prompt return of cyclic activity, with ovulation and full fertility, now well documented, provides irrefutable evidence against the idea that ovarian atrophy is a danger. The notio'n that fertility might be.preserved assumes that, in the absence of ovulation, no loss of follicles occurs butt -if this were the case, women with numerois pregnancies would have correspondingly delayed menopauses.' This is certainly not so and there seems no reason to doubt that follicle atresia,'the principal cause of follicle loss, proceeds at a more or less uniform rate regardless of whether ovulation isg'or is not occurring.'
A further suggestion,' in relation to the ovaries, is that oral contraceptives might be mutagenic. As far as I know there is neither observational nor experimental evidence for this possibility.
Because the continuous administration of cestrogens to experimental rodents has sometimes led to pituitary tumour formation, this possibility has been raised as a danger from long-term oral contraception. The seven or more years' experience to date has certainly not yet confirmed it in the human and, since for oral 'contraception administration is discontinuous, it is pirobable that the situation with regard to tumouri'production is quite different from that when there is continuous exhibition. These remarks also apply to the postulated carcinogenic action on the genital tract; it is the oestrogen component which is apt to be held suspect in this respect, even though no authority who has studied the matter has been able to find any convincing evidence that exogenously administered aestrogens have ever caused cancer in the human. There is no doubt that oral contraceptives decrease the secretion of ovarian aestrogens and it is probable that the added cestrogen scarcely makes good the resulting deficiency. Women taking oral contraceptives are in a progestogen-rather than an aestrogendominated state and the experimental evidence suggests that progestogens are, if anything, anticarcinogenic in relation to the genital tract. In fact, it is not altogether fanciful to suggest that the long-term use of oral contraceptives might reduce the incidence of genital carcinoma. The data, admittedly limited, from Puerto Rico, a region with a particularly high incidence of genital carcinoma, seem so far to be consonant with such a possibility. The aggravating effect of cestrogenprogestogen mixtures on existing breast cancer seems, on the other hand, a distinct possibility, so that the use of oral contraceptives in affected patients would probably be unwise. Rapid increase in size in uterine fibromyomata has been reported in some patients on oral contraceptives but this reaction is by no means invariable and the factors involved are not understood. It is known that some steroids, such as the corticosteroids and some nitrogen anabolic agents, affect carbohydrate metabolism, reducingcarbo-
